Michel Bouvier

Chairman, Scientific Advisory Board at Domain Therapeutics SA

Michel Bouvier

Michel Bouvier

Chairman, Scientific Advisory Board at Domain Therapeutics SA

Overview
RelSci Relationships

44

Number of Boards

2

Relationships
RelSci Relationships are individuals Michel Bouvier likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder at Applied Genetic Technologies Corp.

Relationship likelihood: Strong

Professor Emeritus, Biochemistry at Brandeis University

Relationship likelihood: Strong

Professor, Department of Biochemistry & Molecular Biophysics at Washington University in St.Louis - School of Medicine

Relationship likelihood: Strong

Chief Executive Officer, Director & Chief Scientific Officer at Domain Therapeutics SA

Relationship likelihood: Strong

Chief Executive Officer at Amicus Therapeutics, Inc.

Relationship likelihood: Strong

Founder at Domain Therapeutics SA

Relationship likelihood: Average

Founder at Domain Therapeutics SA

Relationship likelihood: Average

Founder at Domain Therapeutics SA

Relationship likelihood: Average

Vice President-Research & Development at Vertex Pharmaceuticals

Relationship likelihood: Average

Partner at Seventure Partners SA

Relationship likelihood: Average

Paths to Michel Bouvier
Potential Connections via
Relationship Science
You
Michel Bouvier
Chairman, Scientific Advisory Board at Domain Therapeutics SA
Boards & Committees
Chairman, Scientific Advisory Board
2014 - Current

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm’s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Israël, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in October 2001 and is headquartered in Illkirch-Graffenstaden, France.

Member, Scientific Advisory Board
Tenure Unconfirmed

Amicus Therapeutics, Inc. is a biotechnology company, which is engaged in the discovery, development and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.